| | Business Summary | | Sequenom,
Inc.
is
engaged
in
the
effort
to
identify
genes
and
genetic
variations
with
significant
impact
on
human
health.
Utilizing
a
novel
population
genetics
approach,
Sequenom
is
systematically
identifying
potential
disease-related
genes
that
affect
significant
portions
of
the
overall
population.
Using
its
technologies,
information
and
scientific
strategy,
the
Company
is
translating
data
generated
from
the
Human
Genome
Project
into
medically
important
applications.
The
Company's
MassARRAY
technology
enables
the
screening
of
virtually
all
human
genes
in
relation
to
all
diseases
and
in
large
numbers
of
individuals.
The
combination
of
its
technology
and
population
genetics
strategy
is
generating
results
that
enable
the
Company
to
capture
intellectual
property
to
utilize
in
new
drugs,
therapies
and
diagnostics.
By
focusing
on
disease
genes
with
a
broad
population
impact,
the
Company
expects
to
bring
new
therapeutic
products
to
the
market
while
maximizing
the
return
on
drug
development. | | More
from
Market Guide: Expanded
Business Description |
| | Financial Summary | | Sequenom,
Inc.
is
primarily
involved
in
the
research
and
development
of
high
definition
DNA
analysis
tools
for
industrial
biomedical
and
life
science
applications,
used
for
improving
health,
agriculture
and
livestock.
For
the
six
months
ended
6/30/01,
revenues
totaled
$12.6
million,
up
from
$3.5
million.
Net
loss
fell
21%
to
$15.7
million.
Results
reflect
continued
strong
demand
for
MassARRAY
products,
partially
offset
by
expansion
of
the
Company's
gene
discovery
efforts. | | More
from
Market Guide: Significant
Developments |
| | | | FY1999
Compensation | | Pay | Exer | |
| Helmut Schuhsler, Ph.D., 40
Chairman
of Directors | -- | -- | Antonius Schuh, Ph.D., 36
Pres,
CEO, Director | $221K | $688K | Hubert Koster, Ph.D., 59
Vice
Chairman | 753K | 1.6M | Delbert Foit, Jr., 53
COO | -- | -- | Karsten Schmidt, Ph.D., 38
Managing
Director, Sequenom GmbH | -- | -- | | Dollar
amounts are as of 31-Dec-1999 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors:
Expanded
List, Bios,
Compensation,
Options
|
|
![[one-year price graph]](http://chart.yahoo.com/c/0b/s/sqnm.gif)